Emergent BioSolutions (EBS) Misses Q2 EPS, Revenue
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $1.86 -2.11%
EPS Growth %: +73.8%
Financial Fact:
Selling, general and administrative: 40.69M
Today's EPS Names:
ESCA, LICT, NKSH, More
EPS Growth %: +73.8%
Financial Fact:
Selling, general and administrative: 40.69M
Today's EPS Names:
ESCA, LICT, NKSH, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of ($0.86), $1.24 worse than the analyst estimate of $0.38. Revenue for the quarter came in at $242.7 million versus the consensus estimate of $270.94 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BayCom Corp (BCML) Misses Q1 EPS by 4c
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Intuitive Surgiical (ISRG) beats earnings, revenue expectations in Q1
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
